Pediatric-onset multiple sclerosis (POMS) is associated with higher likelihood of cognitive impairment and faster decline in information-processing efficiency, in adulthood, than adult-onset multiple ...

A prospective analysis suggested that those with pediatric-onset multiple sclerosis (MS) who experienced earlier disease-modifying treatment initiation may be less vulnerable to disease progression.

Few studies have investigated the interplay among age at onset of disease, age at initiation of disease-modifying therapy, and clinical outcomes in patients with MS. According to these investigators, ...

Research indicates those with pediatric-onset multiple sclerosis (POMS) may have reduced memory performance compared with healthy controls. Individuals with pediatric-onset multiple sclerosis (POMS) ...

Please provide your email address to receive an email when new articles are posted on . Risk of treatment discontinuation at 2 years was six times higher with moderately effective therapies. Highly ...

Using highly effective therapies (HETs) as the first-line treatment for pediatric-onset multiple sclerosis (POMS) offers better control of disease activity than starting with moderately effective ...

WEST PALM BEACH, Florida — Patients with pediatric-onset multiple sclerosis (POMS) have less higher education and greater use of high-efficacy disease-modifying therapy (DMT), compared with patients ...

Please provide your email address to receive an email when new articles are posted on . Most participants were unemployed, with nearly half receiving disability benefits. Unemployment was associated ...

Our one-year fellowship program is designed with the goal of training pediatric neurologists to provide compassionate and high-quality care for pediatric patients with multiple sclerosis, related ...